Our study revealed that palbociclib possesses the ability to overcome cisplatin resistance and suppress proliferation of bladder cancer cells characterized by elevated levels of IGF2BP3 protein expression. The gene discussed is IGF2BP3; the disease is urinary bladder cancer.